NASDAQ: NKTR · Biotechnology
Over the past week, Nektar Therapeutics (NKTR) pulled in about 96 mentions across Reddit, X and news, and the read is an Adanos Sell. The crowd averages 30% bullish but is sharply divided: News runs 57% bullish while Reddit sits at just 0%. Wall Street is more constructive, with 10 of 12 analysts rating NKTR a buy.
There is little buzz around NKTR this week and little agreement on direction, which is why it reads as a Sell.
Wall Street’s 83% buy share sits next to a crowd that ranges from Reddit at 0% to News at 57%. No other tracker puts the two side by side.
12 analysts have weighed in: a Strong Buy consensus: 10 buy calls against 0 sell, with an average 12-month price target of $141.40.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits just below the neutral line, momentum is improving and the 3 sources disagree sharply, so the read is a Sell.
Analysts sit 53 points above the crowd average of 30%, the professionals are more constructive than retail. The split is inside the crowd: News reads 57% bullish while Reddit sits at 0%, a 57-point spread that single-source trackers miss.
Over the 30-day window, Nektar Therapeutics (NKTR) buzz held subdued around 34.7 while the price drifted down 41.0% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 2M shares. Updated Oct 10, 2026. Over the last 7 trading days, NKTR lost 12.4%. Buzz activity in the recent week averaged 42.4 and was variable, swinging between 26.9 and 60.0. Recent volume is running above the 30-day average, suggesting heightened trading interest. Daily crowd sentiment leaned bullish on 10 of the 21 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for NKTR and 2110+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live NKTR sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Oct 10, 2026.
| Adanos signal | Sell |
|---|---|
| Analyst consensus | Strong Buy (10 / 2 / 0) |
| Crowd bullish (7d) | 30% |
| Avg price target | $141.40 |
| Most bullish source | News, 57% |
| Most bearish source | Reddit, 0% |
| Sentiment spread | 57 pts |
| Mentions (7d) | 96 |
| Market cap | $1.39B |
| P/E · Forward P/E | n/a · 34.0 |
| EPS · Beta | -$18.96 · 1.3 |
| Revenue (TTM) | $54.6M · -288% margin |
| Industry | Biotechnology |
Based on aggregated sentiment from Reddit, X and News sources, Nektar Therapeutics (NKTR) currently carries an Adanos sell signal with 93/100 conviction. The current cross-source average reads 30% bullish across 3 active sources. Those sources contribute 96 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
Reddit discussion around Nektar Therapeutics (NKTR) is fairly quiet with 1 mentions over the last 7 days; the 30-day context spans 3 tracked subreddits. The 7-day tone is 0% bullish; 3-day activity momentum is stable, suggesting steady attention.
The crowd reads bearish on Nektar Therapeutics (NKTR), averaging 30% bullish across 3 tracked sources over the last 7 days. The two ends of the range are News at 57% bullish and Reddit at 0%, a 57-point spread. On the professional side, 10 of 12 analysts rate NKTR a buy.
Of the 12 analysts covering Nektar Therapeutics (NKTR), 10 rate it a buy, 2 a hold and 0 a sell, for a strong buy consensus. The average price target is $141.40. That puts the street ahead of the crowd, which averages 30% bullish.
Nektar Therapeutics (NKTR)'s cross-source average is bearish at 30% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. X reads 33% bullish, News reads 57% bullish and reddit coverage is the most negative at 0% bullish. The combined signal points to broad sell-side pressure with 93/100 conviction.
The cross-source average is bearish for Nektar Therapeutics (NKTR) at 30% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. The most bearish reading is reddit at 0% bullish. 3-day activity momentum is rising across X. The sell signal carries 93/100 conviction.
X is the dominant discussion channel with 88 mentions (92% of total volume). News contributes 7 mentions and Reddit contributes 1 mention. The cross-source average is bearish at 30% bullish, while x is the only source with rising 3-day activity. Source readings are split: 1 source leans bullish and 2 sources lean bearish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. NKTR's sell signal at 93/100 conviction reflects a bearish cross-source average at 30% bullish. Source readings are split: 1 source leans bullish and 2 sources lean bearish. It is a research shortcut, not financial advice.
The NKTR sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Sell signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key